References
- IQVIA. (2024). The Global Use of Medicines 2024: Outlook to 2028.
- NHS England. (2024). Innovative Medicines Fund.
- Trowman, R., Migliore, A., & Ollendorf, D. A. (2023). Health technology assessment 2025 and beyond: lifecycle approaches to promote engagement and efficiency in health technology assessment. International Journal of Technology Assessment in Health Care, 39(1), e15. doi:10.1017/S0266462323000090
- UK Government. (2024). 2024 Voluntary Scheme for Branded Medicines Pricing, Access and Growth.
- U.S. Department of Health & Human Services. (2024). New HHS Reports Illustrate Potential Positive Impact of Inflation Reduction Act on Prescription Drug Prices.
References
- Thomson, S., Cylus, J., Al Tayara, L., Gallardo Martínez, M., García-Ramírez, J., Cerezo Cerezo, J., Karanikolos, M., & Evetovits, T. (2024). Monitoring progress towards universal health coverage in Europe: a descriptive analysis of financial protection in 40 countries. Lancet Regional Health Europe, 37(2), doi.org/10.1016/j.lanepe.2023.100826
- WHO Regional Office for Europe. (2023). Can people afford to pay for health care? Evidence on financial protection in 40 countries in Europe. WHO Regional Office for Europe. Retrieved from https://iris.who.int/handle/10665/374504.
- WHO Regional Office for Europe. (2024). UHC watch [Online database]. Copenhagen: WHO Regional Office for Europe. Retrieved from https://apps.who.int/dhis2/uhcwatch.
References
- European Commission, Directorate-General for Competition. (2019). Competition enforcement in the pharmaceutical sector (2009–2017): European competition authorities working together for affordable and innovative medicines. https://data.europa.eu/doi/10.2763218954.
- European Commission, Directorate-General for Competition. (2024). Update on competition enforcement in the pharmaceutical sector (2018–2022): European competition authorities working together for affordable and innovative medicines. https://data.europa.eu/doi/10.2763427709.
- European Competition Network. (2021). Joint statement by the European Competition Network (ECN) on application of competition law during the Corona crisis. https://competition-policy.ec.europa.eu/system/files/2021-03/202003_joint-statement_ecn_corona-crisis.pdf.
Reference
- This study, and adapted version of this abstract, was published in:
- Joosse, I. R., van den Ham, H. A., Mantel-Teeuwisse, A. K., & Suleman, F. (2023). Alignment in the registration, selection, procurement and reimbursement of essential medicines for childhood cancers in South Africa. BMJ Global Health, 8(9), e012309. https://doi.org/10.1136/bmjgh-2023-012309.
References
- Schneider, P., Fischer, S., & Heindl, B. (2021). Internationale Preisanalyse von Medikamenten im patentabgelaufenen Markt. Study protocol.
- Schneider, P., & Vogler, S. (2019). Price studies for specific medicines. In: Medicine price surveys, analyses and comparisons (pp. 113–164). Elsevier.
- Vogler, S., Schneider, P., & Zimmermann, N. (2019). Preparing price studies–key methodological decisions. In: Medicine Price Surveys, Analyses and Comparisons (pp. 269–318). Elsevier.
References
- Hendrickx, A., Vos, B., Vrancken, J., Bourda, A., & Demyttenaere, B. (2022). What would be the impact of fair prices for medicines in Belgium? Research based on 7 cases. https://www.aim-mutual.org/wp-content/uploads/2023/11/Solidaris-Impact-Fair-price-in-Belgium-01-2023-def.pdf.
- International Association of Mutual Benefit Societies. (2021). Fair pricing calculator https://fairpricingcalculator.eu/.
- Muth, L., Neitemeier, S., Dammann, D., Steimle, T., & Glaeske, G. (2021). AIM fair price calculator for patent-protected medicines - an approach to calculating fairer pharmaceutical prices in the EU and beyond. https://www.aim-mutual.org/wp-content/uploads/2021/10/TK_AIM-Fair-Pricing-Calculator-EN_Rev.pdf.
Reference
- Schlander, M., Hernandez-Villafuerte, K., Cheng, C. Y., Mestre-Ferrandiz, J., & Baumann, M. (2021). How much does it cost to research and develop a new drug? A systematic review and assessment. PharmacoEconomics, 39, 1243–1269.
Reference
- HAS. (2023). Accès précoce des médicaments : un bilan positif après deux ans de mise en place du dispositif. https://www.has-sante.fr/upload/docs/application/pdf/2023-10/synthese_aap_2ans.pdf.
References
- Abdraimova, A., Besançon, S., Portocarrero, J., et al. (2022). Management of type-1 diabetes in low- and middle-income countries: comparative health system assessments in Kyrgyzstan, Mali, Peru, and Tanzania. Diabetic Medicine, e14891. doi:10.1111/dme.1481.
- Hogerzeil, H. V. (n.d.). National Diabetes Programme: Tanzania’s transition. Health Action International. https://haiweb.org/publication/national-diabetes-programme-tanzanias-transition/
Reference
- WHO. (n.d.). Lista de Medicamentos esenciales. https://www.paho.org/es/documentos/22a-lista-modelo-oms-medicamentos-esenciales-ingles.
References
- Habl, C., Schneider, P., Sebesta, R., & Nemeth, G. (2018). Euripid guidance document external reference pricing (ERP). Written as part of the Project ‘664317 / Statistical data for medicinal product pricing EURIPID’ which has received funding from the European Union’s Health Programme (2014-2020). https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/EURIPID_GuidanceDocument_V8.1_310718_5_0.pdf.
- Vogler, S., & Schneider, P. (2019). Assessing data sources for medicine price studies. International Journal of Technology Assessment in Health Care, 35(2), 1-10. doi:10.1017/S0266462319000138
- World Health Organization. (2020). Guideline on country pharmaceutical pricing policies. (2nd ed.). https://www.who.int/publications/i/item/9789240011878
References
- National Health Authority. (2020). Journey from HBP 1.0 to HBP 2.0. https://pmjay.gov.in/sites/default/files/2020-01/Journey-from-HBP-1.0-to-HBP-2.0.pdf.
- National Health Authority. (2021). Official website of Pradhan Mantri Jan Arogya Yojana (PM-JAY). https://pmjay.gov.in/.
- Ramsay, C. R., Matowe, L., Grilli, R., Grimshaw, J. M., & Thomas, R. E. (2003). Interrupted time series designs in health technology assessment: Lessons from two systematic reviews of behavior change strategies. International Journal of Technology Assessment in Health Care, 19(4), 613–623.
References
- Lawlor, R., Wilsdon, T., Darquennes, E., Hemelsoet, D., Huismans, J., Normand, R., & Roediger, A. (2021). Accelerating patient access to oncology medicines with multiple indications in Europe. Journal of Market Access & Health Policy, 9(1), 1964791. doi:10.1080/20016689.2021.1964791
- OECD. (2020). Addressing challenges in access to oncology medicines. https://www.oecd.org/health/health-systems/Addressing-Challenges-in-Access-to-Oncology-Medicines-Analytical-Report.pdf.
References
- Rodwin, M. A. (2021). Common pharmaceutical price and cost controls in the United Kingdom, France, and Germany: lessons for the United States. International Journal of Health Services, 51(3), 379–91.
- Rodwin, M. A. (2022). Assessing US pharmaceutical policy and pricing reform legislation in light of European price and cost control strategies. Journal of Health Politics, Policy and Law, 47(6), 755–78.
- Rodwin, M. A., & Lantos, J. D. (2024). How will medicare negotiate drug prices, and what impact will it have? Health Affairs Forefront. Advance online publication. doi: 10.1377/forefront.20240212.393864.
Reference
- Danna-Buitrago, J. P., & Stellian, R. (2022). A New Class of Revealed Comparative Advantage Indexes. Open Econ Rev, 33, 477–503. https://doi.org/10.1007/s11079-021-09636-4
Reference
- Grössmann, N., Wolf, S., Rothschedl, E., & Wild, C. (2021). 12-years of European cancer drug approval – a systematic investigation of the “magnitude of clinical benefit”. ESMO Open. https://doi.org/10.1016/j.esmoop.2021.100166
References
- La Revue Prescrire. (2023). Towards better patient care: Drugs to avoid in 2023. Prescrire International, 32(245), 50-1–50-11. Available at: La Revue Prescrire.
- Mintzes, B., & Vitry, A. (2021). ‘Drugs to avoid’: Can we improve prescribing appropriateness? Drug and Therapeutics Bulletin, 59(11), 162. doi: 10.1136/dtb.2021.000029.
Reference
- Godman, B., Hill, A., Simoens, S., Selke, G., Selke Krulichová, I., Zampirolli Dias, C., et al. (2021). Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications. Expert Review of Pharmacoeconomics & Outcomes Research, 21(4), 527–540.
Reference
- Singh, M. P., Popli, R., Brar, S., Rajsekar, K., Sachin, O., Naik, J., Kumar, S., Sinha, S., Singh, V., Patel, P., & Verma, R. (2022). CHSI costing study–challenges and solutions for cost data collection in private hospitals in India. PLoS One, 17(12), e0276399.
Reference
- Vogler, S., & Fischer, S. (2020). How to address medicines shortages: Findings from a cross-sectional study of 24 countries. Health Policy, 124(12), 1287–1296.
References
- Kalindjian, A., Ralph, L., Middleton, S., Parkinson, S., Phillips, W. D., Romanelli, R. J., Alom, S., Rodriguez-Rincon, D., Marjanovic, S., Slag, M., & van der Erf, S. (2022). The financial ecosystem of pharmaceutical R&D: An evidence base to inform further dialogue. Dutch government. https://www.tweedekamer.nl/kamerstukken/brieven_regering/detail?id=2022Z12825&did=2022D26469.
- Parkinson, S., Romanelli, R. J., Phillips, W., Alom, S., & Marjanovic, S. (2021). The financial ecosystem of pharmaceutical R&D: Future scenarios for the financial ecosystem of pharmaceutical R&D (Annex C). Dutch government. https://www.tweedekamer.nl/kamerstukken/brieven_regering/detail?id=2022Z12825&did=2022D26469.
References
- Directorate for Pharmaceutical Affairs. (2021). Horizon scanning. Retrieved December 18, 2023. https://healthservices.gov.mt/en/pharmaceutical/Pages/horizon-scanning.aspx.
- Vogler, S. (2022). “Ready for the future?” – status of national and cross-country horizon scanning systems for medicines in European countries. GMS German Medical Science, 20, Doc05. https://doi.org/10.3205/000307
Reference
- Levesque, J. F., Harris, M. F., & Russell, G. (2013). Patient-centred access to health care: conceptualising access at the interface of health systems and populations. International Journal for Equity in Health, 12, 18. https://doi.org/10.1186/1475-9276-12-18
Reference
- World Health Organization. (2020). WHO guideline on country pharmaceutical pricing policies. https://www.ncbi.nlm.nih.gov/books/NBK570140/
Reference
- National Pharmaceutical Pricing Authority, Department of Pharmaceuticals, Government of India. (n.d). NPPA Affordable Medicines for All: Medical Devices. https://www.nppaindia.nic.in/en/homelinks/medical-devices-2/.
Reference
- Németh, G., Mágó, M. L., Kaló, Z., Lám, J., Balogh, T., & Brodszky, V. (2023). A concept for multi-winner tenders for medicinal products with balancing between efficient prices, long-term competition and sustainability of supply. Frontiers of Medicine, 10, 1282698. doi: 10.3389/fmed.2023.1282698